Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: A case-control study

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 4, 2015, Pages 368-378

  Vodkin, I ^a   Valasek, M A ^b   Bettencourt, R ^c   Cachay, E ^d   Loomba, R ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACIDOPHILE; ADULT; AGE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CRYPTOGENIC CIRRHOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LOBULAR INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; RISK FACTOR; SEX; STEATOHEPATITIS; TOBACCO; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; BIOPSY; FATTY LIVER; HEALTH STATUS INDICATOR; HIV INFECTIONS; INFLAMMATION; LIVER FUNCTION TEST; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREVALENCE;

ADULT; BIOPSY; BODY MASS INDEX; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HEALTH STATUS INDICATORS; HIV INFECTIONS; HUMANS; INFLAMMATION; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE;

EID: 84921439750     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13052     Document Type: Article

References (41)

1. Vernon G, Baranova A, Younossi ZM,. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
2. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G,. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.
3. Williams CD, Stengel J, Asike MI, et al,. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
4. Loomba R, Sanyal AJ,. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-90.
5. Chalasani N, Younossi Z, Lavine JE, et al,. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
6. Zarrinpar A, Loomba R,. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 36: 909-21.
7. Loomba R, Abraham M, Unalp A, et al,. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-51.
8. Fracanzani AL, Valenti L, Bugianesi E, et al,. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-8.
9. Kneeman JM, Misdraji J, Corey KE,. Secondary causes of nonalcoholic fatty liver disease. Ther Adv Gastroenterol 2012; 5: 199-207.
10. Safar Zadeh E, Lungu AO, Cochran EK, et al,. The liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 2013; 59: 131-7.
11. Bugianesi E, Leone N, Vanni E, et al,. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
12. Adams LA, Lymp JF, St Sauver J, et al,. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
13. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ,. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
14. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R,. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2014 [Epub ahead of print]
15. Angulo P, Bugianesi E, Bjornsson ES, et al,. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-9 e4.
16. (UNAIDS) JUNPoHA. Global report: UNAIDS report on the global AIDS epidemic 2013 (August 10, 2014). Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/unaids-global-report-2013-en.pdf
17. Antiretroviral Therapy Cohort C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96.
18. Weber R, Sabin CA, Friis-Moller N, et al,. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Int Med 2006; 166: 1632-41.
19. Lewden C, May T, Rosenthal E, et al,. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-8.
20. Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K,. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377: 1198-209.
21. Guaraldi G, Squillace N, Stentarelli C, et al,. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-7.
22. Crum-Cianflone N, Dilay A, Collins G, et al,. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50: 464-73.
23. Amorosa V, Synnestvedt M, Gross R, et al,. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39: 557-61.
24. Keithley JK, Duloy AM, Swanson B, Zeller JM,. HIV infection and obesity: a review of the evidence. J Assoc Nurses AIDS Care 2009; 20: 260-74.
25. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A,. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113-9.
26. Worm SW, Friis-Moller N, Bruyand M, et al,. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. Aids 2010; 24: 427-35.
27. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
28. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
29. Bambha K, Pierce C, Cox C, et al,. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. Aids 2012; 26: 599-607.
30. Kleiner DE, Brunt EM, Van Natta M, et al,. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
31. Wanless IR, Lentz JS,. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
32. Wagenknecht LE, Scherzinger AL, Stamm ER, et al,. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity 2009; 17: 1240-6.
33. Kallwitz ER, Kumar M, Aggarwal R, et al,. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008; 53: 1358-63.
34. Mohammed SS, Aghdassi E, Salit IE, et al,. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients. J Acquir Immune Defic Syndr 2007; 45: 432-8.
35. Ingiliz P, Valantin MA, Duvivier C, et al,. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49: 436-42.
36. Barbaro G, Iacobellis G,. Metabolic syndrome associated with HIV and highly active antiretroviral therapy. Curr Diab Rep 2009; 9: 37-42.
37. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S,. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 2004; 292: 210-8.
38. Carr A, Miller J, Law M, Cooper DA,. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. Aids 2000; 14: F25-32.
39. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS,. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33: 577-84.
40. Akhtar MA, Mathieson K, Arey B, et al,. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastro Hepatol 2008; 20: 1194-204.
41. Nishijima T, Gatanaga H, Shimbo T, et al,. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection. PLoS ONE 2014; 9: e87596.